September 21, 2021, Palo Alto, California – Koji Tanabe, Founder and CEO of I Peace, Inc., has been selected by the judges of World Biz Magazine’s annual awards to be a recipient of the “Top 100 Innovation CEO – 2021”. [Read more…]
Bio-Techne Launches ExCellerate™ iPSC Expansion Medium
A novel animal component-free medium that supports robust expansion and maintenance of human pluripotent stem cells.
Minneapolis, September 14, 2021 — Bio-Techne Corporation (NASDAQ: TECH) Bio-Techne announced the launch of a new medium for the expansion and maintenance of induced pluripotent stem cells (iPSCs) for use in both research and translational workflows. The ExCellerate™ iPSC Expansion Medium is the latest addition to Bio-Techne’s comprehensive portfolio of products and services for Regenerative Medicine. It is designed to fit seamlessly into their offerings for stem cell workflows, including cell isolation, reprogramming, genome engineering, cell expansion, differentiation and characterization. [Read more…]
Treefrog Therapeutics Secures $75M in Series B Financing To Advance a Pipeline of Stem Cell-Derived Cell Therapies and Deploy Proprietary C-Stem™ Technology in the USA & Japan
Frederic Desdouits, PhD, named chief executive officer. Co-founder Kevin Alessandri, PhD, relocates to Boston to drive TreeFrog Therapeutics’ expansion in the U.S.
Bordeaux, France/September 13th, 2021 – TreeFrog Therapeutics, a privately held French-based biotech startup focused on developing safe and affordable stem cell-derived cell therapies for millions of patients, today announced the successful closing of a $75 million (€64M) Series B financing round, bringing the total funding to date to $83 million (€70M). [Read more…]
Hemostemix. The Canadian Biotech that Could Change Healthcare as We Know It.
Hemostemix Inc. (“Hemostemix”) (TSX Venture:HEM; OTCQB:HMTXF) is a publicly traded clinical-stage biotech company that develops and commercializes blood-derived stem cell therapies for medical conditions lacking adequate treatment options. Importantly, it is one of the first clinical-stage biotech companies to test a stem cell therapy within an international, multi-center Phase II clinical trial for patients with critical limb ischemia (“CLI”). CLI is a severe form of peripheral artery disease (“PAD”) that is caused by reduced blood flow to the extremities. [Read more…]
I Peace expands its clinical-grade iPSC banking service leveraging mass manufacturing capability
September 7, 2021, Palo Alto, California – I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech startup focusing on Nobel Prize-winning technology of induced pluripotent stem cells (iPSCs) expands its personalized iPSC banking service. I Peace launched its clinical-grade personalized iPSC banking service in 2020 in Japan and has already banked several individuals’ iPSCs. The company will collaborate with I’rom Group Co., Ltd. (Japan) to make the service available for clients at every corner of the country. Using this as proof of concept, I Peace plans to launch the iPSC banking service in the U.S. as the next phase of its business expansion. [Read more…]
- « Previous Page
- 1
- …
- 85
- 86
- 87
- 88
- 89
- …
- 201
- Next Page »